Editas Medicine, Inc. (EDIT) Fair Value 2026

EDIT · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.4 /10

32 fundamental signals · 9 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Editas Medicine, Inc. (EDIT) trades at $3.04, approximately 232% above CirclFi’s Bayesian DCF fair value of $0.92. QOC: 6.4/10. 9/13 models active.

Key Facts

Ticker
EDIT
Price
$3.04
Quality Score
6.4/10
Value Trap Risk
—/100
Models Active
9/13
Last Updated
Strength: 9 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Editas Medicine, Inc. (EDIT) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Editas Medicine, Inc. (EDIT) appears overvalued as of : the median of 9 independent fair value estimates is $1.22, 59.9% below the current price of $3.04. Estimates range from $0.54 to $2.73. EDIT scores 6.4/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Editas Medicine, Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($3.04)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.92 -69.9%
CUCE Ensemble
Low Conviction
 $1.22 -59.9%
First Chicago
Medium Conviction
 $0.82 -73.1%
Dynamic NAV
Medium Conviction
 $1.35 -55.7%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Editas Medicine, Inc. (EDIT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Editas Medicine, Inc.'s intrinsic value is estimated at $1.34. Trading at its current price of $3.04, the valuation engine raises significant caution: 9 of 9 models flag downside risk, projecting an average implied return of -56.0%. The most optimistic model, PWERM, places fair value at $2.73 (-10.1%), while Sentiment SOTP — the most conservative — estimates $0.54 (-82.2%). This +72.1% gap reflects genuine analytical uncertainty about Editas Medicine, Inc.'s intrinsic worth.

What Do the Models Say About EDIT?

9 of 13 models are currently active for EDIT. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates EDIT's intrinsic value at $0.92, implying -69.9% downside from the current price. See which stocks rank higher →

How Does EDIT Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, EDIT ranks #30 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Editas Medicine, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is EDIT a Value Trap?

The Value Trap algorithm is not active for EDIT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Editas Medicine, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Editas Medicine, Inc. scores 6.4 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +72.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every EDIT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across EDIT's 9 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Editas Medicine, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Editas Medicine, Inc.

What is Editas Medicine, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Editas Medicine, Inc. (EDIT) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.92. The Quality of Company score is 6.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is EDIT overvalued or undervalued right now?

At $3.04, 0 of 9 active models suggest EDIT may be undervalued, while 9 indicate potential overvaluation. The median of all 9 fair value estimates is $1.22, 59.9% below the current price of $3.04 — a consensus view that EDIT is overvalued. The assessment depends on which methodology best fits Editas Medicine, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 6.4 mean for EDIT?

Editas Medicine, Inc.'s QOC of 6.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on EDIT?

CirclFi analyzes EDIT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is EDIT a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for EDIT at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Editas Medicine, Inc. (EDIT) has a median fair value of $1.22 — 59.9% below the current price of $3.04 — as of 2026-07-15.” Source: circlfi.com/stock/EDIT/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on EDIT.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access